NCT00107978

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,035 (actual)
• Sponsor: Cumberland Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study 0018 (NCT00107978) compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.

Conditions

• Staphylococcal Skin Infection

Interventions

Type	Name	Description
DRUG	Telavancin	Telavancin 10 mg/kg/day, IV for up to 14 days.
DRUG	Vancomycin	Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.

Timeline

• Start date: 2005-02-01
• Primary completion: 2006-05-01
• Completion: 2006-05-01
• First posted: 2005-04-12
• Last updated: 2019-01-16
• Results posted: 2010-02-01

Locations

1 site across 1 country: United States